collection
https://read.qxmd.com/read/27502891/risk-of-lymphoma-in-patients-exposed-to-antitumour-necrosis-factor-therapy-results-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis
#1
JOURNAL ARTICLE
Louise K Mercer, James B Galloway, Mark Lunt, Rebecca Davies, Audrey L S Low, William G Dixon, Kath D Watson, Deborah P M Symmons, Kimme L Hyrich
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of lymphoma compared with the general population. There are concerns that tumour necrosis factor inhibitors (TNFi) may exacerbate this risk. However, since the excess risk of lymphoma in RA is related to the cumulative burden of inflammation, TNFi may conversely reduce the risk of lymphoma by decreasing the burden of inflammation. The aim of this study was to compare the risk of lymphoma in subjects with RA treated with TNFi with those treated with non-biological therapy...
March 2017: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/24375097/rfc-1-80g-a-is-a-genetic-determinant-of-methotrexate-efficacy-in-rheumatoid-arthritis-a-huge-review-and-meta-analysis-of-observational-studies
#2
Tabitha N Kung, Jessica Dennis, Yiqing Ma, Gang Xie, Vivian Bykerk, Janet Pope, Carter Thorne, Edward Keystone, Katherine A Siminovitch, France Gagnon
Background: Associations have been reported between candidate genes and response to methotrexate (MTX) in rheumatoid arthritis (RA) patients, but most of the studies have been small and yielded conflicting results. Systematic reviews of all variants are lacking, and meta-analyses have been reported for only the two most commonly studied variants. Methods: We performed a systematic review of genetic variant associations with MTX efficacy and toxicity and performed meta-analysis of the most commonly studied single nucleotide polymorphism lacking prior cumulative analysis...
December 24, 2013: Arthritis and Rheumatism
https://read.qxmd.com/read/25371313/the-ability-of-the-2013-american-college-of-cardiology-american-heart-association-cardiovascular-risk-score-to-identify-rheumatoid-arthritis-patients-with-high-coronary-artery-calcification-scores
#3
COMPARATIVE STUDY
Vivian K Kawai, Cecilia P Chung, Joseph F Solus, Annette Oeser, Paolo Raggi, C Michael Stein
OBJECTIVE: Patients with rheumatoid arthritis (RA) have increased risk of atherosclerotic cardiovascular disease that is underestimated by the Framingham Risk Score (FRS). We undertook this study to test the hypothesis that the 2013 American College of Cardiology/American Heart Association (ACC/AHA) 10-year risk score would perform better than the FRS and the Reynolds Risk Score (RRS) in identifying RA patients known to have elevated cardiovascular risk based on high coronary artery calcification (CAC) scores...
February 2015: Arthritis & Rheumatology
https://read.qxmd.com/read/25359382/methotrexate-in-combination-with-other-dmards-is-not-superior-to-methotrexate-alone-for-remission-induction-with-moderate-to-high-dose-glucocorticoid-bridging-in-early-rheumatoid-arthritis-after-16-weeks-of-treatment-the-carera-trial
#4
RANDOMIZED CONTROLLED TRIAL
P Verschueren, D De Cock, L Corluy, R Joos, C Langenaken, V Taelman, F Raeman, I Ravelingien, K Vandevyvere, J Lenaerts, E Geens, P Geusens, J Vanhoof, A Durnez, J Remans, B Vander Cruyssen, E Van Essche, A Sileghem, G De Brabanter, J Joly, S Meyfroidt, K Van der Elst, R Westhovens
OBJECTIVES: To compare the efficacy and safety of intensive combination strategies with glucocorticoids (GCs) in the first 16 weeks (W) of early rheumatoid arthritis (eRA) treatment, focusing on high-risk patients, in the Care in early RA trial. METHODS: 400 disease-modifying antirheumatic drugs (DMARD)-naive patients with eRA were recruited and stratified into high risk or low risk according to classical prognostic markers. High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7...
January 2015: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/25471471/discontinuation-of-tumour-necrosis-factor-inhibitors-in-patients-with-rheumatoid-arthritis-in-low-disease-activity-persistent-benefits-data-from-the-corrona-registry
#5
JOURNAL ARTICLE
Arthur Kavanaugh, Susan J Lee, Jeffrey R Curtis, Jeffrey D Greenberg, Joel M Kremer, Lilian Soto, Carol J Etzel, Vanessa Cox, Kazuki Yoshida, George W Reed, Daniel H Solomon
BACKGROUND: There is increasing interest in discontinuing biological therapies for patients with rheumatoid arthritis (RA) achieving good clinical responses, provided patients maintain clinical benefit. METHODS: We assessed patients with RA from the Corrona registry who discontinued treatment with their first tumour necrosis factor inhibitor (TNFi) while in low-disease activity (LDA) or lower levels of disease activity. Patients were followed until they lost clinical benefit, defined as increased disease activity or change in RA medications...
June 2015: Annals of the Rheumatic Diseases
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.